The effects of obesity on cancer treatment efficacy remain unclear, as both beneficial and detrimental modulations of the tumor immune microenvironment have been reported. We compared 68Ga-NOTA-GZP ...

Most well-differentiated neuroendocrine tumors (NETs) express high levels of somatostatin receptors, particularly subtypes 2 and 5. Somatostatin analogs (SSAs) bind to somatostatin receptors and are ...

The value of nuclear medicine imaging for diagnosing infections, was first recognized nearly 50 y ago (1). The 3-phase bone scan was for many years the radionuclide test of choice for musculoskeletal ...

The aggressiveness and molecular complexity of glioblastoma multiforme challenges the current standard-care therapy, limiting the median overall survival to 14–16 mo (1). In the last few decades, new ...

Treatment of non–small cell lung cancer (NSCLC) has advanced considerably over the past 40 y. In addition to the advent of molecularly targeted therapies, inhibition of immune checkpoints using ...

Radiopharmaceutical therapy (RPT) is defined as the delivery of radioactive atoms to tumor-associated targets. In RPT, imaging is built into the mode of treatment since the radionuclides used in RPT ...

The expanding field of theranostics combines the use of both diagnostic and therapeutic drugs that target shared molecular markers of disease. The diagnostic component of a theranostic drug pair is ...

177 Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial ...

Introduction: MNPR-101 is a humanized monoclonal antibody to the urokinase plasminogen activator receptor (uPAR). uPAR expression is elevated in several aggressive cancers but rarely if at all ...

Pretargeted radioimmunodiagnosis and radioimmunotherapy aim to efficiently combine antitumor antibodies and medicinal radioisotopes for high-contrast imaging and high–therapeutic-index (TI) tumor ...

Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177 Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine Prediction of 177 ...

Introduction: The recent success of inhibitors against immune checkpoint proteins (e.g. CTLA-4, PD-L1), which are thought in part to stimulate T cell responses against tumors, and chimeric antigen ...